Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: A study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Have a read: https://www.m3india.in/contents/journal/a-study-to-evaluate-the-efficacy-and-safety-of?utm_campaign=unset&utm_medium=share&utm_source=ref_wa